Outlook Therapeutics Stock (NASDAQ:OTLK)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.89

52W Range

$0.16 - $3.39

50D Avg

$0.39

200D Avg

$0.88

Market Cap

$45.25M

Avg Vol (3M)

$15.90M

Beta

0.98

Div Yield

OTLK Company Profile

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 14, 2016

Website

OTLK Performance

OTLK Financial Summary

	Sep 25	Sep 24	Sep 23
Revenue	$1.41T	-	-
Operating Income	$-67.06T	$-71.70M	$-53.13M
Net Income	$-62.42T	$-75.37M	$-58.98M
EBITDA	$-67.06T	$-72.09M	$-57.38M
Basic EPS	$-1.79	$-4.06	$-4.72
Diluted EPS	$-1.79	$-4.06	$-4.72

Fiscal year ends in Sep 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Aug 14, 24 | 8:30 AM

Q2 24May 16, 24 | 8:30 AM

Peer Comparison

Ticker	Company
OSTX	OS Therapies Incorporated
COEP	Coeptis Therapeutics, Inc.
CUE	Cue Biopharma, Inc.
IPSC	Century Therapeutics, Inc.
SPRB	Spruce Biosciences, Inc.
NRXP	NRx Pharmaceuticals, Inc.
IOBT	IO Biotech, Inc.
MDCX	Medicus Pharma Ltd. Common Stock
EQ	Equillium, Inc.
HOWL	Werewolf Therapeutics, Inc.